Life Sciences
Carl June and Michel Sadelain were awarded the 2024 BREAKTHROUGH PRIZE in Life Sciences for genetically engineered T cells – key players in the body’s immune system – with synthetic receptors termed chimeric antigen receptors (CARs) to instruct T cells to recognize the cancer cells of individual patients. These CAR T cells have remarkable rates of success against liquid cancers including types of leukemia, lymphoma and myeloma. For some patients, the tumors have been entirely eradicated and have not returned, years after treatment.
Michel Sadelain is an active member of Minerva Biotechnologies’ Scientific Advisory Board. Dr. Sadelain works with the Minerva team to reach our goal of adapting current CAR T technology so that it is effective against solid tumor cancers such as breast, lung, prostate and pancreatic cancers.
We congratulate all the winners as well as the selection committees for their excellent choices!
“Humanity’s collective intelligence is our most significant achievement. Great scientists, and Breakthrough Prize laureates among them, are at the forefront of this incredible phenomenon in our Universe.”
– Yuri Milner